Trial
NCT00087776
Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
American Regent, Inc.
Collaborators
—
Condition
Malignant Melanoma
Intervention
Taxoprexin
Why stopped
Interim analysis determined that the futility boundary had been crossed and there was no reasonable prospect that statistical significance would be achieved if patient accrual continued
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-23